Why the study?
Does TAVR with a self-expanding prosthesis improve survival at 1 year compared to surgical aortic-valve replacement in patients with severe aortic stenosis at increased surgical risk?
Does TAVR with a self-expanding prosthesis improve survival at 1 year compared to surgical aortic-valve replacement in patients with severe aortic stenosis at increased surgical risk?
Answers are grounded in this paper and cite their sources.
In high-risk patients with severe aortic stenosis, TAVR with a self-expanding prosthesis significantly improves 1-year survival compared to surgical aortic-valve replacement.
In patients with severe aortic stenosis who are at increased surgical risk, TAVR with a self-expanding transcatheter aortic-valve bioprosthesis was associated with a significantly higher rate of survival at 1 year than surgical aortic-valve replacement. (Funded by Medtronic; U.S. CoreValve High Risk Study ClinicalTrials.gov number, NCT01240902.).
No takes yet. Share an insight, caveat, or question.
Adams et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: